← Leaderboards
Marta Chesi
Mayo Clinic Arizona
$7,128,274
Attributed
$8,397,855
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,397,855 · 6
By mechanism
R01$5,095,777 · 3
P50$2,597,456 · 2
UG3$704,622 · 1
Top collaborators
- Peter Leif Bergsagel4 shared
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelCellsBone MarrowMultiple MyelomaMediatingAnemiaTumorImmune SystemClinical TrialsImmunocompetentPlasma CellsIn VivoThalidomidePharmaceutical PreparationsComplexImmunomodulatorsGlucocorticoidsBoneGrowthLenalidomideGeneticNeoplastic CellMalignant NeoplasmsClinically Relevant
Grant awards (21)
Preclinical studies for the immunoprevention of multiple myeloma$704,622
UG3 · FY2025 · CA
preclinical optimization of BCMA directed T cell therapy$621,878
R01 · FY2025 · CA · contact PI
Project 3: Early detection and prevention of MM progression$425,666
P50 · FY2025 · CA · contact PI
preclinical optimization of BCMA directed T cell therapy$590,784
R01 · FY2024 · CA · contact PI
Project 3: Early detection and prevention of MM progression$401,850
P50 · FY2024 · CA · contact PI
preclinical optimization of BCMA directed T cell therapy$621,878
R01 · FY2023 · CA · contact PI
Project 3: Early detection and prevention of MM progression$392,040
P50 · FY2023 · CA · contact PI
Credentialing a Genetically Engineered Clinically-Relevant Mouse Model of Multiple Myeloma$372,131
R01 · FY2023 · CA · contact PI
Credentialing a Genetically Engineered Clinically-Relevant Mouse Model of Multiple Myeloma$372,131
R01 · FY2022 · CA · contact PI
Credentialing a Genetically Engineered Clinically-Relevant Mouse Model of Multiple Myeloma$379,725
R01 · FY2021 · CA · contact PI
Credentialing a Genetically Engineered Clinically-Relevant Mouse Model of Multiple Myeloma$379,725
R01 · FY2020 · CA · contact PI
Credentialing a Genetically Engineered Clinically-Relevant Mouse Model of Multiple Myeloma$379,725
R01 · FY2019 · CA · contact PI
Immunomodulatory Therapy of Multiple Myeloma with SMAC Mimetics$260,101
P50 · FY2019 · CA · contact PI
Immunomodulatory Therapy of Multiple Myeloma with SMAC Mimetics$306,573
P50 · FY2018 · CA · contact PI
PQD2 Rational Combination of Standard Agents and Immunotherapy to Treat Myeloma$344,450
R01 · FY2017 · CA · contact PI
Immunomodulatory Therapy of Multiple Myeloma with SMAC Mimetics$281,365
P50 · FY2017 · CA · contact PI
PQD2 Rational Combination of Standard Agents and Immunotherapy to Treat Myeloma$344,450
R01 · FY2016 · CA · contact PI
Immunomodulatory Therapy of Multiple Myeloma with SMAC Mimetics$263,269
P50 · FY2016 · CA · contact PI
PQD2 Rational Combination of Standard Agents and Immunotherapy to Treat Myeloma$344,450
R01 · FY2015 · CA · contact PI
Immunomodulatory Therapy of Multiple Myeloma with SMAC Mimetics$266,592
P50 · FY2015 · CA · contact PI
PQD2 Rational Combination of Standard Agents and Immunotherapy to Treat Myeloma$344,450
R01 · FY2014 · CA · contact PI